NEW YORK (GenomeWeb) – Quest Diagnostics on Friday said that it expects revenues to grow 3 percent to 5 percent and earnings to grow in the mid- to high-single digits annually from 2017 to 2020.

The Madison, New Jersey-based firm also said it plans to raise its common stock dividend by more than 12 percent to an annual rate of $1.80 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.